Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 4/20 | 0.32 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2768431 | 1.00 | CASP3 (0.33) | CASP3CASP7CXCR2CXCR1NPC1 | |
| SCHEMBL2768551 | 1.00 | CASP3 (0.33) | CASP3CASP7CXCR2CXCR1NPC1 | |
| SCHEMBL2769423 | 0.92 | ALDH1A1 (0.35) | CASP3CASP7NPC1MEN1KMT2A | |
| SCHEMBL2769797 | 0.91 | CXCR2 (0.36) | CASP3CASP7CXCR2MEN1KMT2A | |
| SCHEMBL2769795 | 0.91 | CXCR2 (0.36) | CASP3CASP7CXCR2MEN1KMT2A | |
| SCHEMBL2770412 | 0.91 | CXCR2 (0.36) | CASP3CASP7CXCR2MEN1KMT2A | |
| SCHEMBL6141260 | 0.88 | CASP3 (0.35) | CASP3CASP7RORC | |
| SCHEMBL2768276 | 0.86 | CXCR2 (0.43) | CXCR2CXCR1 | |
| SCHEMBL2768897 | 0.86 | CXCR2 (0.43) | CXCR2CXCR1 | |
| SCHEMBL2768274 | 0.86 | CXCR2 (0.43) | CXCR2CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1272175-B1 | N,N'-DIARYL GUANIDINES AS IL-8 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2010-04-21 | — | — | EP | disclosed |
| EP-1272175-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-08-31 | — | — | EP | disclosed |
| US-6680317-B2 | N-(PHENYL)-N*-(2-HYDROXY-3-AMINOSULFONYLPHENYL)GUANIDINE DERIVATIVES; CHEMOKINE INHIBITORS; RESPIRATORY, CARDIOVASCULAR, RHEUMATIC, BRAIN, AND NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2004-01-20 | — | — | US | disclosed |
| US-20030216375-A1 | Il-8 receptor anatagonists | GLAXOSMITHKLINE LLC | 2003-11-20 | — | — | US | disclosed |
| EP-1272175-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001072960-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216375-A1 | Il-8 receptor anatagonists | CXCL8, CCR8, IL1R1 | CASP3 2136/4885CASP7 722/4885CXCR2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.